

1 Genomic and clinical characteristics of campylobacteriosis in Australia

2 Danielle M Cribb^{1*}, Cameron RM Moffatt², Rhiannon L Wallace³, Angus T McLure¹, Dieter Bulach^{4,5},

3 Amy V Jennison², Nigel French⁶, Mary Valcanis⁵, Kathryn Glass¹, Martyn D Kirk¹.

4 1. National Centre for Epidemiology and Population Health, the Australian National University,
5 Canberra, Australia

6 2. Queensland Health Forensic and Scientific Services, Coopers Plains, Brisbane, Australia

7 3. Agriculture and Agri-Food Canada, Agassiz Research and Development Centre, Agassiz,
8 British Columbia, Canada

9 4. Melbourne Bioinformatics, The University of Melbourne, Melbourne, Australia

10 5. Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for
11 Infection and Immunity, The University of Melbourne, Melbourne, Australia

12 6. Tāwharau Ora|School of Veterinary Science, Massey University, Palmerston North, New
13 Zealand

14
15 * corresponding author

16 Danielle.Cribb@anu.edu.au (DC)

17

18 Abstract

19 *Campylobacter* spp. are a common cause of bacterial gastroenteritis in Australia, primarily acquired
20 from contaminated meat. We investigated the relationship between genomic virulence characteristics
21 and the severity of campylobacteriosis, hospitalisation, and other host factors.

22 We recruited 571 campylobacteriosis cases from three Australian states and territories (2018–2019).
23 We collected demographic, health status, risk factors, and self-reported disease data. We whole
24 genome sequenced 422 *C. jejuni* and 84 *C. coli* case isolates along with 616 retail meat isolates. We
25 classified case illness severity using a modified Vesikari scoring system, performed phylogenomic
26 analysis, and explored risk factors for hospitalisation and illness severity.

27 On average, cases experienced a 7.5-day diarrhoeal illness with additional symptoms including
28 stomach cramps (87.1%), fever (75.6%), and nausea (72.0%). Cases aged ≥ 75 years had milder
29 symptoms, lower Vesikari scores, and higher odds of hospitalisation compared to younger cases.
30 Chronic gastrointestinal illnesses also increased odds of hospitalisation. We observed significant
31 diversity among isolates, with 65 *C. jejuni* and 21 *C. coli* sequence types. Antimicrobial resistance genes
32 were detected in 20.4% of isolates, but multidrug resistance was rare (0.04%). Key virulence genes
33 such as *cdtABC* (*C. jejuni*) and *cadF* were prevalent (>90% presence) but did not correlate with disease
34 severity or hospitalisation. However, certain genes appeared to distinguish human *C. jejuni* cases from
35 food source isolates.

36 Campylobacteriosis generally presents similarly across cases, though some are more severe.
37 Genotypic virulence factors identified in the literature to-date do not predict disease severity but may
38 differentiate human *C. jejuni* cases from food source isolates. Host factors like age and comorbidities
39 have a greater influence on health outcomes than virulence factors.

40 Keywords: antimicrobial resistance, Campylobacter, clinical outcomes, severity, virulence, whole
41 genome sequencing.

42 Author summary

43 This study focused on *Campylobacter*, a common cause of gastroenteritis in Australia. We explored
44 the relationship between *Campylobacter's* genomic characteristics and disease severity,
45 hospitalisation, and host-related factors.

46 In 2018 – 2019, we collected data from 571 campylobacteriosis cases from Eastern Australia, focusing
47 on demographics, health status, risk factors, and self-reported symptoms. We sequenced 422 *C. jejuni*
48 and 84 *C. coli* case isolates and 616 retail meat isolates. We used a modified Vesikari scoring system
49 to assess illness severity, performed phylogenomic analysis, and explored hospitalisation and severity
50 risk factors.

51 Cases experienced an average 7.5-day period of diarrhoea with additional symptoms including
52 stomach cramps, fever, and nausea. Older individuals (75+ years) had milder symptoms but a higher
53 chance of hospitalisation. Those with chronic gastrointestinal conditions faced increased
54 hospitalisation odds. Case isolates showed considerable diversity. Antimicrobial resistance genes were
55 detected in some isolates, but multidrug resistance was rare. Virulence genes did not predict severity
56 or hospitalisation, but some genes did differentiate between case and food source *C. jejuni* isolates.

57 Host-related factors including age and comorbidities are more important in determining health
58 outcomes.

59

60 Introduction

61 *Campylobacter* spp. are the most commonly reported cause of bacterial gastroenteritis globally [1],
62 with Australia having among the highest rates in industrialised countries [2-4]. Most *Campylobacter*
63 infections are acquired from consumption of contaminated meat, primarily poultry [1, 5, 6]. The
64 clinical features of campylobacteriosis range from mild acute illness with diarrhoea, abdominal
65 cramps, and fever to severe enterocolitis with prolonged abdominal pain and bloody diarrhoea [7, 8].
66 While disease is mostly self-limiting, some cases require antimicrobial therapy and hospitalisation [7,
67 9]. Some symptoms and host factors (e.g., age and chronic illness) are more likely to predict healthcare
68 use for acute gastrointestinal illness [10, 11]. Previous studies have found vomiting, bloody diarrhoea,
69 infective dose, fever, and loss of appetite associated with longer illness duration and risk of
70 hospitalisation [12, 13].

71 Pathogen virulence and host susceptibility factors explored in microbiological studies may have
72 implications for disease presentation and outcomes for *Campylobacter* spp. However, specific
73 virulence mechanisms associated with severe illness have not been clearly defined due to the genetic
74 diversity and uniqueness of the pathogen [14-16]. The main mechanisms associated with pathogenesis
75 in enteric bacteria are motility, adhesion, colonisation, toxin production, invasion, and immune
76 modulation [8, 16-20].

77 Identifying specific genes or gene combinations responsible for particular virulence phenotypes
78 enables understanding of the mechanisms of *Campylobacter* infection. While microbiological studies
79 have identified genes associated with putative virulence factors, there is a lack of epidemiological
80 studies confirming the role these genes play in disease manifestation. In this study we characterise
81 notified Australian campylobacteriosis cases by severity and compare with the genomic characteristics
82 of *Campylobacter* spp. isolated from food and humans.

83 Methods

84 Case selection and recruitment

85 We recruited 571 notified campylobacteriosis cases from the Australian Capital Territory (ACT), Hunter
86 New England health district of New South Wales (NSW), and Queensland (Qld) between February 2018
87 and October 2019, as part of a previously described large Australian study [6, 21]. Suspected
88 campylobacteriosis cases provided stool samples to local pathology laboratories to identify and isolate
89 the pathogen. Samples that were positive for *Campylobacter* spp. were reported to the state or
90 territory public health department. Isolates were referred to reference laboratories and processed for
91 whole genome sequencing (WGS). Cases, or their legal guardian if aged less than 18 years, provided
92 consent for study enrolment. Interviews were generally conducted within two weeks of laboratory
93 notification, by either ACT public health unit staff (ACT cases) or by a computer-assisted telephone
94 interview team (NSW and Qld cases). Interviewers collected information on case characteristics
95 (demographics, medication use, health conditions), a list of self-reported symptoms, and disease
96 characteristics. Cases were asked to confirm their diarrhoeal status during illness (>3 loose bowel
97 movements in any 24-hour period), the date of illness onset, that no household member had
98 diarrhoea or tested positive for *Campylobacter* in the four weeks prior to illness onset, and that they
99 had not travelled outside of Australia in the two weeks prior to illness onset [21].

100 Modified Vesikari Scoring System

101 We modified the Vesikari scoring system (VSS) [22] to characterise illness severity (Table 1): retained
102 duration of diarrhoea in days and maximum number of diarrhoeal stools in a 24-hour period; replaced
103 the 'treatment type' variable (i.e., rehydration or hospitalisation) with 'healthcare use' (primary care,
104 1–2 days in hospital, or ≥ 3 days in hospital), and; substituted the presence of symptoms for clinical
105 characteristics as these data were not collected from our self-reported cases. We defined
106 hospitalisation as being admitted overnight due to campylobacteriosis. These modifications are
107 consistent with studies that categorised bacterial gastroenteritis in paediatric cases [23, 24]. We

108 allocated equal weighting to variables associated with the course of disease as well as each reported
109 symptom apart from blood in stool, which was given two points (Table 1) [25]. We classified cut-offs
110 for mild, moderate, and severe disease as ≤ 8 points, 9–12 points, and ≥ 13 points respectively, in line
111 with previous scoring systems [22–24].

112 **Table 1.** Modified Vesikari scoring system for campylobacteriosis in Australian children and adults, 2018–2019.

	Score			
	0	1	2	3
Symptom presentation				
Vomiting	No	Yes	-	-
Self-reported fever	No	Yes	-	-
Stomach cramps	No	Yes	-	-
Headache	No	Yes	-	-
Nausea	No	Yes	-	-
Muscle and body aches	No	Yes	-	-
Blood in stool	No	-	Yes	-
Course of disease				
Duration of diarrhoeal illness (days)	0	1–3	4–6	≥ 7
Maximum number of bowel movements in any 24-hour period	$<3^*$	3–5	6–10	≥ 11
Healthcare use	-	Primary care (notified case)	1–2 days in hospital	≥ 3 days in hospital
Score classification: ≤ 8 mild, 9–12 moderate, ≥ 13 severe				
*Exclusion criterion for case definition				

113 Food sample collection

114 Raw chicken meat and offal (organ meat) and beef, lamb, and pork offal were collected from retail
115 outlets in NSW, Qld, and Victoria (chicken only) from 2017–2019, and from the ACT in 2018, as
116 previously described [26, 27]. Offal samples included giblets, neck, liver, kidney, heart, and tongue. As
117 *Campylobacter* spp. prevalence is generally low on beef, lamb, and pork meat, offal was sampled to
118 obtain a suitable number of isolates for WGS.

119 Whole genome sequencing and genomic analysis

120 For each *Campylobacter* isolate, genomic DNA was extracted and WGS was performed using an
121 Illumina NextSeq500 (Illumina, San Diego, California, USA) as described previously [27]. In total, we
122 sequenced 508 isolates from human stool samples and 616 isolates from retail meat and offal. Kraken2

123 was used to confirm taxonomic classification and isolate purity
124 (<https://pubmed.ncbi.nlm.nih.gov/31779668/>); two isolates from two human cases were confirmed
125 as *C. lari* and were excluded from this analysis. *De novo* assembly of the genome sequence for each
126 isolate from sequencing reads was performed using SPAdes
127 (<https://pubmed.ncbi.nlm.nih.gov/32559359/>). The multi-locus sequence type (MLST) was
128 determined from each isolate using the MLST software (v2.19.0; <https://github.com/tseemann/mlst>)
129 and the PubMLST *Campylobacter jejuni/coli* database [28]. Isolate genome sequences were also
130 screened for resistance determinants using the abriTAMR pipeline (v1.0.7; <https://github.com/MDU->
131 [PHL/abritamr](https://github.com/MDU-PHL/abritamr)) and the AMRFinderPLUS database (v3.10.16;
132 <https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/>). Virulence genes
133 present in each isolate genome sequence were detected using Abricate
134 (<https://github.com/tseemann/abricate>) with genes from the Virulence Factor Database (VFDB) [29].
135 The parameters used for gene detection were the top hit with >80% gene coverage and >80% nucleic
136 acid sequence identity. Abricate was found to be unsuitable for detecting the *porA* and the *flaA* gene
137 in this set of isolates. The paralogous *flaA* and *flaB* genes caused assembly issues which resulted in
138 incomplete *flaA* gene assemblies. The peptide sequence
139 ADKAMDEQLKILDITIKTKATQAAQDGQSLKTRTM from near the N-terminus of FlaA was found to be
140 encoded in a contig from each assembly. Subsequently, the presence of the complete *flaA* and *flaB*
141 genes was inferred by mapping reads from each isolate to the *flaA* gene of *C. jejuni* strain NCTC11168.
142 For *porA*, a protein level detection using the PorA protein from *C. jejuni* strain NCTC11168 as the
143 subject for a blast search against the assembled genome of each isolate was used due to sequence
144 identity less than 80%. Core genome comparison of isolates within a species was performed using
145 Bohra (<https://github.com/MDU-PHL/bohra>). The genome sequences of *C. jejuni* strain RM1221
146 (NC_003912) and *C. coli* strain 76339 (NC_022132) were used as reference genome sequences for the
147 *C. jejuni* and *C. coli* core genome comparisons respectively.

148 Inference of antimicrobial resistance phenotype

149 We used resistance genes and mutations to infer phenotypic resistance (Table S1) in agreement with
150 our previous phenotypic testing results [30]. We investigated chromosomal mutations in the *bla*_{OXA-61}
151 promoter region, the 23S rRNA gene, and the quinolone resistance determining region of *gyrA*, as
152 previously described [27]. Ampicillin (AMP) resistance was inferred from a point mutation at position
153 57 in the *bla*_{OXA-61} promoter region, associated with gene expression inactivation [31]. Resistance to
154 erythromycin (ERY) was determined based on the nucleotide at positions 2074 and 2075 of the 23S
155 rRNA gene [32]. Ciprofloxacin resistance (CIP) was determined by examining the amino acid at position
156 86 of GyrA (T86I confers resistance) [33]. The presence of the *tet(O)*, *aph(3')-IIIa*, and *erm(B)* genes
157 inferred resistance to tetracycline (TET), gentamicin (GEN), and ERY, respectively [34-36]. We defined
158 multi-drug resistance (MDR) as displaying a resistant gene profile for three or more antimicrobial drug
159 classes [37]. Short-read WGS data for all isolates were deposited to the NCBI Sequence Read Archive
160 under bioprojects PRJNA592186, PRJNA560409, and PRJNA591966
161 (<https://www.ncbi.nlm.nih.gov/sra>) (Table S2).

162 Virulence factor analysis

163 We selected virulence genes that frequently occur in studies of genetic determinants of severe
164 campylobacteriosis in humans [8, 38-40]. We compared the prevalence of each virulence gene in each
165 *Campylobacter* species in Australia with pooled prevalence from a small collection of isolates from
166 international studies. We also assessed virulence genotype clustering and total gene count by MLST.
167 Additionally, we included the total number of virulence genes present in isolates as a categorical
168 predictor variable in generalised linear models described below. After excluding any genes that were
169 present or absent from all isolates, we used virulence genes to predict hospitalisation and long
170 diarrhoeal illness. Further, we compared virulence factors between food and case isolates to
171 determine if these factors predict human campylobacteriosis. We tested multiple predictive modelling
172 methods including random forest, logic regression, and binary discriminant analysis [41-44]. We

173 considered Kappa statistic values >0.3 to indicate that the chosen model performed substantially
174 better than naïve classification.

175 **Statistical analysis**

176 All data analyses were performed with R (version 4.0.2) [45]. We used Pearson's chi square test and
177 Student's t-test to assess statistical differences between categorical variable groups and means (p
178 ≤ 0.05). We fitted a generalised additive model with a logit link to predict prevalence of symptoms and
179 hospitalisation as a smooth function of age [46]. We used generalised linear models to calculate
180 adjusted odds ratios (aORs) for demographic factors, medication use, health conditions and disease
181 profiles on the outcomes of hospitalisation, diarrhoeal disease lasting longer than seven days, and
182 antibiotic prescription following illness. We estimated aORs controlling for age group, gender, and
183 location, including any variables with a p -value ≤ 0.2 in a multivariable model. We used backward
184 stepwise logistic regression to identify variables for the final model (variables with p -values ≤ 0.05),
185 assessing significance, aORs and confidence intervals (CIs), and biological plausibility. We used ggplot2
186 to visualise all data figures, and used iTOL (v5.0) for phylogenetic tree visualisation [47, 48].

187 **Ethics**

188 This study was approved by the Australian National University Human Research Ethics Committee
189 (Ref. 2016/426), ACT Health Human Research Ethics Committee (Ref. ETH.8.17.168), Hunter New
190 England Human Research Ethics Committee (Ref. 17/08/4.03), Qld Health Human Research Ethics
191 Committee (Ref. RD007108), and the University of Melbourne Office of Research Ethics and Integrity
192 (Ref. 1750366.1).

193




194 Results

195 Symptom profiles and severity


196 We included 571 cases from the ACT ($n = 93$), NSW ($n = 178$) and Qld ($n = 300$). The highest proportion
197 of cases (38.8%, 219/565) reported experiencing 11–20 loose bowel movements within a 24-hour
198 period with a mean length of illness of 7.5 days (standard deviation [SD] 4.9), generally increasing with
199 age from 6.4 days (SD 3.0) in 5–14-year-olds to 8.7 days (SD 9.6) in ≥ 75 -year-olds. Case patients
200 reported an average of four symptoms in addition to diarrhoea, frequently including stomach cramps
201 (87.1%; 487/559), fever (75.6%; 428/566) and nausea (72.0%; 393/546). Case age influenced symptom
202 profiles, with symptoms such as stomach cramps, fever, headaches, and blood in stool less commonly
203 reported in older cases (Fig1a and 1b). The proportion of cases hospitalised was 24.9% (142/571),
204 which increased with age from 10.2% (5/49) of 0–4-year-olds to 45.0% (18/40) of ≥ 75 -year-olds
205 (Fig1c). Overall, 49.8% (283/568) of case patients reported that they were prescribed antibiotics
206 following illness, with 59.3% (83/140) of hospitalised cases reporting antibiotic prescription compared
207 to 46.7% (200/428) of non-hospitalised cases ($p = 0.01$). Cases as young as 15 years old reported using
208 proton-pump inhibitors (PPIs), a medication prescribed to treat stomach acid-related gastro-
209 oesophageal disorders and to prevent ulcers [49, 50]. Thirty percent (39/130) of 35–54-year-olds
210 reported using PPIs, increasing to 37.5% (15/40) in ≥ 75 -year-olds. Symptom profiles were generally
211 similar between males and females. However, females were more likely to report stomach cramps
212 (91.1%, 216/237, $p = 0.02$) and nausea (80.7%, 188/233, $p = 0.00$) than males (84.2%, 271/322 and
213 65.5%, 205/313, respectively). There was no significant difference in the probability of hospitalisation
214 (25.5% [84/330] males, 24.1% [58/241] females) or duration of illness (7.4 days [SD 5.0] males, 7.6
215 days [SD 4.8] females). The mean VSS score was 10.7 (95% CI 5.7–15.7) (Fig 2). VSS scores were
216 influenced by age, with scores peaking in 15–34-year-olds (11.7, 95% CI 7.6–15.8) and tapering off in
217 older adults ≥ 75 years (8.8, 95% CI 4.0–13.6) (Fig 3).

218

219 Fig 1. (a) Symptom profiles of Australian campylobacteriosis cases (muscle and body aches, nausea, and
220 stomach cramps), 2018–2019. (b) Symptom profiles of Australian campylobacteriosis cases (blood in stool,
221 fever, headache, and vomiting), 2018–2019. (c) Course of disease characteristics of Australian
222 campylobacteriosis cases (hospitalisation, hospitalisation ≥ 3 days, length of illness ≥ 7 days), 2018–2019. The
223 solid lines indicate estimated prevalence from a univariable generalised additive model with a logit link.
224 Shading around each line represents the 95% confidence interval for the prevalence estimate.




229 Fig 2. Distribution of modified Vesikari Scoring System scores for 571 campylobacteriosis cases in Australia,
230 2018–2019. Bars represent the percentage of cases reporting the corresponding Vesikari Score. Error bars are
231 calculated from binomial confidence intervals using the Pearson-Klopper exact method. Counts are provided
232 above the bar for each Vesikari Score.



233

234 Fig 3. Distribution of modified Vesikari Scoring System scores by age for 571 campylobacteriosis cases in
235 Australia, 2018–2019. The solid line indicates the estimated score from a generalised additive model with a
236 logit link. Shading around the line represents the 95% confidence interval for the score estimate.

237



238

239 We constructed three multivariable models, adjusting for age, sex, and location for the outcomes of
240 hospitalisation, antibiotic prescription, and duration of illness for cases with a sequenced
241 *Campylobacter* isolate ($n = 506$; Tables S3–S5). We found that vomiting (aOR 2.6, 95% CI 1.5–4.6) and
242 chronic gastrointestinal (GI) illness (e.g., Crohn’s disease, irritable bowel syndrome, ulcerative colitis;
243 aOR 4.4, 95% CI 1.8–11.1) were associated with higher odds of hospitalisation (Table S3).

244 Factors associated with an increased odds of antibiotic prescription following illness included having
245 blood in stool (aOR 1.6, 95% CI 1.1–2.4), having diarrhoea lasting longer than seven days (aOR 2.0,
246 95% CI 1.3 – 2.9), and being hospitalised (aOR 1.9, 95% CI 1.1–3.2) (Table S4). Factors associated with
247 increased odds of diarrhoeal disease lasting longer than seven days included having headaches (aOR
248 1.7, 95% CI 1.1–2.6) and taking proton pump inhibitors (PPIs) (aOR 2.0, 95% CI 1.2–3.3) (Table S5). We
249 found a cyclical relationship between hospitalisation, length of illness, and antibiotic prescription
250 following illness with these factors showing as significant in each model. We chose to report the most
251 biologically plausible pathways.

252 Genetic diversity of clinical isolates


253 We included 422 *C. jejuni* and 84 *C. coli* isolates derived from human clinical samples in this study. *C.*
254 *jejuni* isolates were assigned to 65 unique MLSTs while *C. coli* isolates were assigned to 21 (Table S6).
255 The most common sequence types detected were ST50 for *C. jejuni* (17.8%, 75/422), and ST1181 for
256 *C. coli* (27.4%, 23/84) (Table S6; S1 and S2 Figs). Pairwise core genome single nucleotide polymorphism
257 (SNP) distances between *C. jejuni* isolates ranged from zero to ~37k SNPs, while *C. coli* isolates ranged
258 from zero to ~82k SNPs.

259 Antimicrobial resistance genes

260 We detected antimicrobial resistance (AMR) genes and point mutations in 20.4% (103/506) of the
261 human isolates, with MDR genotype profiles in 0.04% (2/506) of isolates (Fig 4, S3 Fig, S4 Fig). Results
262 for resistance determinants in the food isolates are reported elsewhere [27]. We did not detect AMP
263 or CIP genomic resistance genes or mutations in one *C. jejuni* and 21 *C. coli* isolates, although this was

264 not tested phenotypically. The most common resistant mechanism detected was for CIP with 12.3%
265 (62/505) of isolates (*C. jejuni* 13.1% [55/421], *C. coli* 8.3% [7/84]) and for TET at 9.7% (49/506) of
266 isolates (*C. jejuni* 11.1% [47/422], *C. coli* 2.4% [2/84]). An AMP resistant genotype was detected in
267 5.2% (25/485) of isolates (*C. jejuni* 5.7% [24/422], *C. coli* 1.6% [1/63]), with isolates possessing the
268 *bla*_{OXA-184} gene ($n = 3$) or a *bla*_{OXA-61} gene and active promotor ($n = 22$; a point mutation at position 57
269 in the promotor regulates gene expression). A GEN resistant genotype was present in 0.4% (2/506) of
270 isolates (*C. jejuni* 0.2% [1/422], *C. coli* 1.2% [1/84]), and ERY resistant genotype was present in 0.2%
271 (1/506) of isolates (not detected in *C. jejuni*, 1.2% [1/84] in *C. coli*), possessing the 23S rRNA A2075G
272 mutation. Two isolates were inferred to be MDR: one *C. coli* isolate harboured five antimicrobial
273 determinants (AMP, CIP, ERY, GEN, and TET) and one *C. jejuni* isolate harboured four (AMP, CIP, GEN,
274 and TET).

275 Fig 4. Genotypic antimicrobial resistance profiles of 506 *Campylobacter* isolates for ampicillin (AMP),
276 ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), and tetracycline (TET). Isolates were classified as
277 susceptible if they did not possess a known resistance gene or mutation ($n = 403$). The number of isolates
278 possessing each resistance profile is noted above the respective bar. Error bars are calculated from binomial
279 confidence intervals using the Pearson-Klopper exact method.



280

281 Virulence factors

282 Human clinical *C. jejuni* isolates had a median of 96 virulence genes detected (range 82–118) and *C.*
283 *coli* isolates had a median of 72 genes (range 64–86). Two-thirds of screened genes were highly
284 conserved ($\geq 95\%$ present) across isolates in both species, with 68.1% (81/119) for *C. jejuni*, and 68.7%
285 (68/99) for *C. coli*. The *flaA*, *flaB*, and *porA* genes were present in all isolates through additional
286 screening. We detected virulence gene clustering by MLST (Table S6; S1 Fig; S2 Fig). Further, 14 of 19
287 and nine of 12 virulence genes selected for international comparison for *C. jejuni*, and *C. coli*,
288 respectively, were highly conserved across isolates, particularly those associated with adhesion and
289 colonisation (e.g., *cadF*, *porA*, and *pebA*), motility (e.g., *flaA*), cytotoxin production (e.g., *cdtABC*), and
290 invasiveness (e.g., *ciaBC* and *flaC*) (Table 2). Genes associated with immune modulation (e.g., *cstIII* and
291 *neuABC*) were present variably across *C. jejuni* isolates at approximately 35.0%. These genes were rare
292 or absent in *C. coli* isolates. Lipooligosaccharide (LOS) and capsule gene screening was limited to those
293 genes present in *C. jejuni* NCTC 11168.

294 We compared all virulence genes present in either our human isolates and 285 *C. jejuni* and 331 *C. coli*
295 isolates from meat and offal. Virulence gene *pseE/maf5* was more common in *C. jejuni* food isolates
296 than in case isolates while *Cj1421c*, *Cj1422c*, *kpsC*, *rbfC*, *fliK*, *Cj1136*, *Cj1138*, *waaV*, and *wlaN* were
297 more common in *C. jejuni* case isolates (Table S7). No isolates significantly differed between food and
298 human isolates for *C. coli*. We did not observe an association between the total number of virulence
299 genes present and the odds of longer duration of diarrhoeal illness, hospitalisation, or antibiotic
300 prescription following illness (Tables S3–S5). Random forest analyses of 58 *C. jejuni* and 43 *C. coli*
301 virulence genes with less than 100.0% prevalence across isolates did not detect any individual or
302 specific combinations of virulence genes that predicted severe illness or hospitalisation, nor did
303 analysis of 72 *C. coli* genes comparing campylobacteriosis case isolates with food isolates (Kappa < 0.3)
304 (S1 and S2 File). Analysis of 65 *C. jejuni* virulence genes comparing case and food isolates highlighted

305 that some virulence genes such as *fliK*, *Cj1138*, and *Cj1136* were enriched in isolates from humans
306 (Kappa 0.51) (S5 Fig).

307 Table 2. Comparison of prevalence of selected *Campylobacter* virulence genes in Australia and internationally.

Virulence function	Gene	<i>C. jejuni</i>			<i>C. coli</i>		
		Australian prevalence (n = 422) %	International prevalence*		Australian prevalence (n = 84) %	International prevalence*	
			% (range)	n/N isolates (# studies)		% (range)	n/N isolates (# studies)
Motility, adhesion, and colonisation	<i>flaA</i> †	100.0	100.0 (100.0 – 100.0)	185/185 (2)	100.0	–	–
	<i>flhA</i>	99.8	99.4 (99.4 – 99.4)	154/155 (1)	100.0	–	–
	<i>cadF</i>	100.0	99.6 (97.9 – 100)	600/602 (8)	100.0	85.1 (8.3 – 100.0)	63/74 (3)
	<i>jlpA</i>	99.8	98.4 (96.2 – 100.0)	185/188 (3)	–	100.0 (100.0 – 100.0)	9/9 (1)
	<i>porA</i> ‡	100.0	90.4 (87.3 – 100.0)	123/136 (2)	100.0	59.5 (16.7 – 100.0)	25/42 (3)
	<i>pebA</i>	100.0	100.0 (100.0 – 100.0)	205/205 (3)	100.0	100.0 (100.0 – 100.0)	9/9 (1)
Invasion	<i>ciaB</i>	97.6	95.6 (50.0 – 100.0)	483/505 (7)	96.4	100.0 (100.0 – 100.0)	21/21 (2)
	<i>ciaC</i>	100.0	–	–	100.0	–	–
	<i>flaC</i>	100.0	96.8 (88.5 – 100.0)	251/257 (4)	100.0	100.0 (100.0 – 100.0)	42/42 (3)
Cytotoxin production	<i>cdtA</i>	99.3	96.7 (82.6 – 100.0)	442/457 (5)	–	36.5 (13.2 – 100.0)	27/74 (3)
	<i>cdtB</i>	99.5	99.3 (97.1 – 100.0)	601/605 (8)	–	56.5 (49.1 – 100.0)	35/62 (2)
	<i>cdtC</i>	100.0	99.0 (94.1 – 100.0)	384/388 (4)	–	35.1 (15.1 – 100.0)	26/74 (2)
	<i>wlaN</i>	31.8	51.7 (17.4 – 100.0)	164/317 (4)	–	–	–
Immune modulation (lipooligosaccharide; LOS)	<i>htrB</i>	99.8	99.0 (99.0 – 99.0)	101/102 (1)	2.4	28.6 (28.6 – 28.6)	6/21 (1)
	<i>waaC</i>	100.0	99.0 (99.0 – 99.0)	101/102 (1)	96.4	100.0 (100.0 – 100.0)	21/21 (1)
	<i>cstIII</i>	34.8	49.7 (31.4 – 83.6)	78/157 (2)	–	–	–
	<i>neuA</i>	35.1	–	–	–	–	–
	<i>neuB</i>	35.1	33.3 (33.3 – 33.3)	34/102 (1)	1.2	–	–
	<i>neuC</i>	34.6	30.4 (30.4 – 30.4)	31/102 (1)	1.2	4.8 (4.8 – 4.8)	1/21 (1)

* prevalence of international isolates sourced from international studies [8, 38-40, 51-55]. The point estimate is calculated across all isolates. The range is reported highest and lowest prevalence in the included studies. '–' gene was not screened or reported. † *flaA* gene prevalence in Australia determined from presence of amino acids due to *flaA/flaB* paralog interference at nucleotide sequence level. ‡ *porA* gene prevalence in Australia determined from presence of amino acids due to low read quality.

309 Discussion

310 Campylobacteriosis cases in Australia displayed relatively similar disease profiles, although
311 some cases experienced more severe symptoms and outcomes, and *Campylobacter* isolates showed
312 considerable variation in their genome, as in many geographic regions [8]. We found *in silico* AMR
313 determinants in one-fifth of human clinical isolates, with very few isolates possessing MDR genotypes.
314 Many putative virulence genes were highly conserved across patient case and retail meat isolates,
315 suggesting these may be central to the pathogen's fitness regardless of the ability to cause disease.
316 Others, including those associated with immune modulation in microbiological studies, were far less
317 conserved or even rare in human and food isolates, reflecting their less essential role in *Campylobacter*
318 viability [56]. We did not identify any associations between individual or combinations of virulence
319 genes and severe disease characteristics. However, we did detect an association between certain
320 genes and *C. jejuni* case isolates compared with food isolates, namely *fliK*, *Cj1136*, and *Cj1138*.

321 The spectrum of health outcomes from *Campylobacter* infections is complex, but host factors
322 including age, comorbidities, and medication use likely play an important determining role [57]. While
323 cases aged between 15 and 34 years were more likely to report a higher modified VSS score, older
324 cases had higher odds of being hospitalised. A previous study systematically describing acute
325 gastroenteritis symptoms by age group similarly found that older adults were more likely to be
326 hospitalised and have severe illness, but reported symptoms decreased with age [58]. A hospital-
327 based data linkage study in Australia reported that comorbidities were present in 34.5% of cases, and
328 that hospitalisation rates noticeably increased among patients aged over 60 years [57]. These studies
329 also found increases in invasive infection, hospitalisation, length of illness and mortality accompanied
330 increasing age [57, 58]. Other factors beyond traditional symptoms of gastroenteritis may be more
331 likely to result in hospitalisation for older cases, such as dehydration or loss of appetite [13, 58]. Our
332 study found that over 30% of cases aged ≥ 35 -years-old had used PPIs prior to illness and that use was
333 associated with longer duration of diarrhoea. This is consistent with a data linkage study that found

334 that PPI use was significantly associated with infectious gastroenteritis hospitalisation [50]. While PPIs
335 are considered a safe and effective medication, approved for long-term use, many patients are
336 unaware of the increased risks of infectious gastrointestinal illness and subsequent hospitalisation
337 that may accompany their use. While certain symptoms may indicate a need for hospitalisation, the
338 overall severity of disease does not necessarily predict hospitalisation. Instead, the age of a case is the
339 most significant determinant of the symptoms they experience and their need for seeking healthcare.

340 While previous genomic epidemiological studies have explored the role of virulence factors in
341 campylobacteriosis, we did not detect any direct relationship between human clinical disease
342 outcomes and the presence of individual virulence genes, combinations of virulence genes, or total
343 number of virulence genes [16, 59]. However, random forest analysis of *C. jejuni* isolates found genes
344 associated with the flagellar hook length gene (*fliK*) and LOS synthesis (*Cj1136* and *Cj1138*) to be more
345 prevalent in case than food isolates. As food is the primary vehicle for *Campylobacter* this finding
346 suggests these genes are important for exposure to translate into clinical disease [60, 61].
347 *Campylobacter* have developed a symbiotic relationship with avian and mammalian species [62].
348 There are likely to be a range of genes and gene combinations that have developed to maintain this
349 relationship. Additionally, poultry hosts carry a wide variety of *Campylobacter* as part of their normal
350 flora; genes curated for symbiosis in poultry may cause disease in humans.

351 Animal models have been used to study *Campylobacter* virulence, but current models are
352 unable to successfully reproduce diarrhoeal illness seen in humans [63-65]. Due to this lack of a
353 suitable animal model, understanding *Campylobacter* virulence mechanisms remains limited.
354 Nevertheless, expression of factors associated with pathogen motility, adhesion, invasion, and toxin
355 production may play a role in *Campylobacter* infection [17, 54, 66, 67]. In this study, the *flhA* and *flaA*
356 genes associated with motility were highly conserved across both *C. jejuni* and *C. coli* isolates,
357 consistent with previous findings [19, 38, 54]. Genes associated with adhesion and colonisation of
358 epithelial cells (i.e., *cadF*, *jlpA*, *porA*, and *pebA*) were also highly conserved in our study isolates and in

359 those investigated previously [38, 52, 54, 55]. In particular, the *cadF* gene is considered an essential
360 gene for adhesion to intestinal cells during the initial stages of campylobacteriosis [17, 52, 54].
361 Similarly, the presence of the *ciaB* and *flaC* genes are considered critical for the invasion of epithelial
362 cells [66]. However, our study results indicate that even in the absence of *ciaB*, clinical disease can
363 occur.

364 Cytolethal distending toxin (CDT) is a commonly distributed toxin across Gram-negative
365 bacteria (e.g., *Shigella* and *Escherichia coli*) and is well characterised in *Campylobacter* spp. [18, 59].
366 CDT operates by promoting intestinal epithelial cell damage and death and is implicated in severe
367 illness caused by *C. jejuni* [19, 68, 69]. Previous studies have suggested that all three gene subunits of
368 the *cdtABC* operon are required for full toxin function [70-72]. Global prevalence of the *cdtABC* operon
369 is high in *C. jejuni* strains but is variable in *C. coli* strains; the *cdtABC* genes were absent in the *C. coli*
370 isolates in our study and ranged from ~13% to 100% across international studies. A previous study
371 found gene differences between *Campylobacter* species, attributing this to a reliance on *C. jejuni*-
372 focused research for understanding virulence [40]. We detected high prevalence of the *cdtABC* operon
373 in *C. jejuni* isolates in our study (>99%), but a previous study comparing diarrhoeal and non-diarrhoeal
374 campylobacteriosis cases detected a much lower prevalence of 76.5% in the non-diarrhoeal cases,
375 indicating that this gene cluster may play a role in development of diarrhoea [8].

376 The functions of individual genes associated with the LOS (i.e., *htrB*, *waaC*, *cstIII*, *wlaN*,
377 *neuABC*) are not well defined, but are thought to be implicated in the development of Guillain-Barré
378 syndrome (GBS), an immunoreactive condition where nervous system receptors are targeted and
379 damaged by the host immune response [39]. The function of these genes is to sialyate *Campylobacter*
380 LOS on the surface of *C. jejuni* cells, mimicking sialylation on gangliosides found on human peripheral
381 nerve cells; this molecular mimicry can trigger GBS [73, 74]. The *wlaN*, *cstIII* and *neuABC* genes were
382 present in approximately one third of *C. jejuni* isolates and were mostly absent in *C. coli*. Further

383 investigation is needed to elucidate the relationship between the expression of these genes and
384 development of GBS.

385 In our previously published Australian study of *Campylobacter* genomics, we reported that
386 the prevalence of AMR determinants was low in *Campylobacter* isolates compared to other high-
387 income countries [30]. Here, we observed a high rate of antibiotic use following infection, regardless
388 of hospitalisation status, length of illness, or case age. Australian prescription guidelines recommend
389 the use of azithromycin, CIP, or norfloxacin for those with severe disease or in vulnerable groups [75].
390 While AMR is low in Australia, attributed to regulations on the prescription of quinolones in humans
391 and food-producing animals [76], growing levels of AMR is a global issue and antimicrobial
392 stewardship is a priority for public health. High prescription rates should be investigated further to
393 ensure optimal patient care while combating antibiotic resistance. Previous studies have examined
394 relationships between virulence markers and AMR [38, 66, 72], with one study reporting a relationship
395 between resistance to fluoroquinolones and TET and the presence of the *virB11* and *wlaN* genes [38]
396 and another with resistance to TET or ERY and *cdtA* and *dnaJ* genes [72]. We observed some clustering
397 of AMR genes by sequence type but did not identify any relationships between AMR and virulence
398 genes or severe disease outcomes.

399 Our study cases were recruited from among cases notified to a health department, meaning
400 that all cases experienced symptomatic illness requiring care and therefore mild or asymptomatic
401 cases were unlikely to have been recruited [10, 25]. Further, cases from the ACT and NSW were largely
402 recruited from hospital-based laboratory service samples suggesting that our hospitalisation rate is
403 not representative of the general hospitalisation rate for campylobacteriosis. An ACT-based study
404 estimated that 13.6% of campylobacteriosis cases were hospitalised, increasing to 20.0% when non-
405 admitted emergency department visits were included [57]. We relied on self-reported symptoms from
406 cases, which may be less reliable than a clinical assessment by a healthcare professional. Some
407 symptoms can be subjective and may not be accurately reported (e.g., fever) or respondents may be

408 reluctant to report them. Older respondents and those with poorer memory or pre-existing health
409 conditions may have experienced issues with recall, particularly when asked about specific symptoms,
410 resulting in recall bias. Finally, we explored a subset of known putative virulence-associated genes
411 sourced from the VFDB. This was not a comprehensive list and did not explore all virulence genes
412 noted in the literature. We included a small number of studies and isolates in our international gene
413 comparison, which is unlikely to be representative of global gene prevalence. As research into
414 virulence determinants continues, further genes and gene combinations should be explored to
415 understand their role in disease.

416 In this study, we did not find direct associations between genetic markers of virulence and
417 disease outcomes for *Campylobacter*. However, we did detect associations between certain virulence
418 genes and human *C. jejuni* isolates compared with food isolates. Our study provides valuable insights
419 into the genomic diversity, the prevalence of virulence markers, and the low prevalence of antibiotic
420 resistance among *Campylobacter* isolates. To continue uncovering unknown aspects of the pathogen,
421 *Campylobacter* surveillance should continue to incorporate WGS to provide high-resolution data,
422 particularly for developing baseline estimates of genomic characteristics in mild, moderate, and
423 severe disease to understand associations with severity. To support this, researchers conducting
424 cohort studies should consider examining virulence factor prevalence between symptomatic and
425 asymptomatic cases, as well as the development of more severe sequelae such as GBS in cases. Future
426 studies in Australia should follow international studies that have investigated the presence or absence
427 of certain virulence genes, AMR, and the molecular relationships between human clinical and source
428 isolates to enable a more comprehensive understanding of the pathogenesis of campylobacteriosis
429 [38, 77, 78].

430

431

432 Acknowledgements

433 The authors would like to thank the extended CampySource Project team, reference panel, and
434 additional contributors to the study. The CampySource Project team comprises three working groups
435 and a reference panel. The working groups focus on food and animal sampling, epidemiology and
436 modelling, and genomics. The reference panel includes expert representatives from government and
437 industry. The study includes the following partner organisations: the Australian National University,
438 Massey University, University of Melbourne, Queensland Health, Queensland Health Forensic and
439 Scientific Services, New South Wales Food Authority, New South Wales Health, Hunter New England
440 Health, Victorian Department of Health and Human Services, Food Standards Australia New Zealand,
441 Commonwealth Department of Health and AgriFutures Australia–Chicken Meat Program.
442 CampySource also collaborates with the following organisations: ACT Health, Sullivan Nicolaides
443 Pathology, University of Queensland, Primary Industries and Regions South Australia, Department of
444 Health and Human Services Tasmania, Meat and Livestock Australia, and New Zealand Ministry for
445 Primary Industries.

446 The CampySource Project Team consists of: Nigel P French, Massey University, New Zealand; Mary
447 Valcanis, The University of Melbourne; Dieter Bulach, The University of Melbourne; Emily Fearnley,
448 South Australian Department for Health and Wellbeing; Russell Stafford, Queensland Health; Amy
449 Jennison, Queensland Health; Trudy Graham, Queensland Health; Keira Glasgow, Health Protection
450 NSW; Kirsty Hope, Health Protection NSW; Themy Saputra, NSW Food Authority; Craig Shadbolt, NSW
451 Food Authority; Arie Havelaar, The University of Florida, USA; Joy Gregory, Department of Health and
452 Human Services, Victoria; James Flint, Hunter New England Health; Simon Firestone, The University of
453 Melbourne; James Conlan, Food Standards Australia New Zealand; Ben Daughtry, Food Standards
454 Australia New Zealand; James J Smith, Queensland Health; Heather Haines, Department of Health and
455 Human Services, Victoria; Sally Symes, Department of Health and Human Services, Victoria; Barbara
456 Butow, Food Standards Australia New Zealand; Liana Varrone, The University of Queensland; Linda
457 Selvey, The University of Queensland; Tim Sloan-Gardner, ACT Health; Deborah Denehy, ACT Health;

458 Radomir Krsteski, ACT Health; Natasha Waters, ACT Health; Kim Lilly, Hunter New England Health;
459 Julie Collins, Hunter New England Health; Tony Merritt, Hunter New England Health; Rod Givney,
460 Hunter New England Health; Joanne Barfield, Hunter New England Health; Ben Howden, The
461 University of Melbourne; Kylie Hewson, AgriFutures Australia–Chicken Meat Program; Dani Cribb, The
462 Australian National University; Rhiannon Wallace, The Australian National University; Angus McLure,
463 The Australian National University; Ben Polkinghorne, The Australian National University; Cameron
464 Moffatt, The Australian National University; Martyn Kirk, The Australian National University; and
465 Kathryn Glass, The Australian National University.

466 References

- 467 1. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global Epidemiology of
468 *Campylobacter* Infection. Clin Microbiol Rev. 2015;28(3):687-720. doi: 10.1128/CMR.00006-
469 15. PubMed PMID: 26062576.
- 470 2. Australian Government Department of Health and Aged Care. National Notifiable Disease
471 Surveillance System - National Communicable Disease Surveillance Dashboard 2023.
472 Available from: <https://nindss.health.gov.au/pbi-dashboard/>.
- 473 3. European Food Safety Authority, European Centre for Disease Prevention and Control. The
474 European Union One Health 2019 Zoonoses Report. EFSA J. 2021;19(2):e06406. doi:
475 10.2903/j.efsa.2021.6406.
- 476 4. Centers for Disease Control and Prevention. FoodNet Fast - Pathogen Surveillance 2022
477 [cited 2023 February]. Available from: cdc.gov/foodnetfast/.
- 478 5. Varrone L, Glass K, Stafford RJ, Kirk MD, Selvey L, CampySource Project Team. A meta-
479 analysis of case-control studies examining sporadic campylobacteriosis in Australia and New
480 Zealand from 1990 to 2016. Aust N Z J Public Health. 2020;44(4):313-9. doi:
481 <https://doi.org/10.1111/1753-6405.12998>.
- 482 6. Cribb DM, Varrone L, Wallace RL, McLure AT, Smith JJ, Stafford RJ, et al. Risk factors for
483 campylobacteriosis in Australia: outcomes of a 2018–2019 case–control study. BMC Infect
484 Dis. 2022;22(1):586. doi: 10.1186/s12879-022-07553-6.
- 485 7. Acheson D, Allos BM. Campylobacter jejuni Infections: Update on Emerging Issues and
486 Trends. Clinical Infectious Diseases. 2001;32(8):1201-6. doi: 10.1086/319760.
- 487 8. Wysok B, Wojtacka J, Hänninen M-L, Kivistö R. Antimicrobial Resistance and Virulence-
488 Associated Markers in Campylobacter Strains From Diarrheic and Non-diarrheic Humans in
489 Poland. Frontiers in Microbiology. 2020;11. doi: 10.3389/fmicb.2020.01799.
- 490 9. Wiczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. Biomed
491 Res Int. 2013;2013:340605. Epub 2013/07/19. doi: 10.1155/2013/340605. PubMed PMID:
492 23865047; PubMed Central PMCID: PMCPCMC3707206.
- 493 10. Elnegaard S, Andersen RS, Pedersen AF, Larsen PV, Søndergaard J, Rasmussen S, et al. Self-
494 reported symptoms and healthcare seeking in the general population--exploring "The
495 Symptom Iceberg". BMC Public Health. 2015;15:685. Epub 2015/07/22. doi:
496 10.1186/s12889-015-2034-5. PubMed PMID: 26195232; PubMed Central PMCID:
497 PMCPCMC4509464.
- 498 11. McAteer A, Elliott AM, Hannaford PC. Ascertaining the size of the symptom iceberg in a UK-
499 wide community-based survey. Br J Gen Pract. 2011;61(582):e1-11. Epub 2011/03/16. doi:
500 10.3399/bjgp11X548910. PubMed PMID: 21401979; PubMed Central PMCID:
501 PMCPCMC3020067.
- 502 12. Gillespie IA, apos, Brien SJ, Frost JA, Tam C, Tompkins D, et al. Investigating vomiting and/or
503 bloody diarrhoea in Campylobacter jejuni infection. Journal of Medical Microbiology.
504 2006;55(6):741-6. doi: <https://doi.org/10.1099/jmm.0.46422-0>.
- 505 13. Hall G, Kirk M, Ashbolt R, Gregory J, Lalor K, Millard G, et al. Results from the National
506 Gastroenteritis Survey 2001 - 2002. National Centre for Epidemiology and Population Health,
507 The Australian National University, 2004.
- 508 14. Wallace RL, Cribb DM, Bulach DM, Ingle DJ, Joensen KG, Nielsen EM, et al. Campylobacter
509 jejuni ST50, a pathogen of global importance: A comparative genomic analysis of isolates
510 from Australia, Europe and North America. Zoonoses and Public Health. 2021;68(6):638-49.
511 doi: <https://doi.org/10.1111/zph.12853>.
- 512 15. Djeghout B, Bloomfield SJ, Rudder S, Elumogo N, Mather AE, Wain J, et al. Comparative
513 genomics of Campylobacter jejuni from clinical campylobacteriosis stool specimens. Gut
514 Pathogens. 2022;14(1):45. doi: 10.1186/s13099-022-00520-1.
- 515 16. Dasti JI, Tareen AM, Lugert R, Zautner AE, Groß U. Campylobacter jejuni: A brief overview on
516 pathogenicity-associated factors and disease-mediating mechanisms. International Journal

- 517 of Medical Microbiology. 2010;300(4):205-11. doi:
518 <https://doi.org/10.1016/j.ijmm.2009.07.002>.
- 519 17. de Oliveira MG, Rizzi C, Galli V, Lopes GV, Haubert L, Dellagostin OA, et al. Presence of genes
520 associated with adhesion, invasion, and toxin production in *Campylobacter jejuni* isolates
521 and effect of temperature on their expression. *Can J Microbiol*. 2019;65(4):253-60. Epub
522 2018/12/12. doi: 10.1139/cjm-2018-0539. PubMed PMID: 30532987.
- 523 18. Silva J, Leite D, Fernandes M, Mena C, Gibbs PA, Teixeira P. *Campylobacter* spp. as a
524 Foodborne Pathogen: A Review. *Front Microbiol*. 2011;2:200. Epub 2011/10/13. doi:
525 10.3389/fmicb.2011.00200. PubMed PMID: 21991264; PubMed Central PMCID:
526 PMCPMC3180643.
- 527 19. Ramires T, de Oliveira MG, Kleinubing NR, de Fátima Rauber Würfel S, Mata MM, Iglesias
528 MA, et al. Genetic diversity, antimicrobial resistance, and virulence genes of thermophilic
529 *Campylobacter* isolated from broiler production chain. *Braz J Microbiol*. 2020;51(4):2021-32.
530 Epub 2020/06/10. doi: 10.1007/s42770-020-00314-0. PubMed PMID: 32514993; PubMed
531 Central PMCID: PMCPMC7688733.
- 532 20. Bolton DJ. *Campylobacter* virulence and survival factors. *Food Microbiol*. 2015;48:99-108.
533 Epub 2015/03/21. doi: 10.1016/j.fm.2014.11.017. PubMed PMID: 25790997.
- 534 21. Varrone L, Stafford RJ, Lilly K, Selvey L, Glass K, Ford L, et al. Investigating locally relevant risk
535 factors for *Campylobacter* infection in Australia: protocol for a case–control study and
536 genomic analysis. *BMJ Open*. 2018;8(12):e026630. doi: 10.1136/bmjopen-2018-026630.
- 537 22. Ruuska T, Vesikari T. Rotavirus Disease in Finnish Children: Use of Numerical Scores for
538 Clinical Severity of Diarrhoeal Episodes. *Scandinavian Journal of Infectious Diseases*.
539 1990;22(3):259-67. doi: 10.3109/00365549009027046.
- 540 23. Schnadower D, Tarr PI, Gorelick MH, O'Connell K, Roskind CG, Powell EC, et al. Validation of
541 the modified Vesikari score in children with gastroenteritis in 5 US emergency departments.
542 *J Pediatr Gastroenterol Nutr*. 2013;57(4):514-9. Epub 2013/05/17. doi:
543 10.1097/MPG.0b013e31829ae5a3. PubMed PMID: 23676445; PubMed Central PMCID:
544 PMCPMC3788842.
- 545 24. Shim DH, Kim DY, Cho KY. Diagnostic value of the Vesikari Scoring System for predicting the
546 viral or bacterial pathogens in pediatric gastroenteritis. *Korean J Pediatr*. 2016;59(3):126-31.
547 Epub 2016/05/18. doi: 10.3345/kjp.2016.59.3.126. PubMed PMID: 27186219; PubMed
548 Central PMCID: PMCPMC4865623.
- 549 25. Hall G, Yohannes K, Raupach J, Becker N, Kirk M. Estimating community incidence of
550 *Salmonella*, *Campylobacter*, and Shiga toxin-producing *Escherichia coli* infections, Australia.
551 *Emerg Infect Dis*. 2008;14(10):1601-9. Epub 2008/10/02. doi: 10.3201/eid1410.071042.
552 PubMed PMID: 18826825; PubMed Central PMCID: PMCPMC2609882.
- 553 26. Walker LJ, Wallace RL, Smith JJ, Graham T, Saputra T, Symes S, et al. Prevalence of
554 *Campylobacter coli* and *jejuni* in retail chicken, beef, lamb and pork products in three
555 Australian states. *Journal of Food Protection*. 2019;82(12):2126-34.
- 556 27. Wallace RL, Bulach DM, Jennison AV, Valcanis M, McLure A, Smith JJ, et al. Molecular
557 characterization of *Campylobacter* spp. recovered from beef, chicken, lamb and pork
558 products at retail in Australia. *PLOS ONE*. 2020;15(7):e0236889. doi:
559 10.1371/journal.pone.0236889.
- 560 28. Jolley KA, Bray, J. E., & Maiden, M. C. J. Open-access bacterial population genomics: BIGSdb
561 software, the PubMLST.org website and their applications. *Wellcome Open Res*.
562 2018;3(124). doi: 10.12688/wellcomeopenres.14826.1.
- 563 29. Liu B, Zheng D, Zhou S, Chen L, Yang J. VFDB 2022: a general classification scheme for
564 bacterial virulence factors. *Nucleic Acids Res*. 2022;50(D1):D912-d7. doi:
565 10.1093/nar/gkab1107. PubMed PMID: 34850947; PubMed Central PMCID:
566 PMCPMC8728188.

- 567 30. Wallace R, Bulach D, McLure A, Varrone L, Jennison A, Valcanis M, et al. Antimicrobial
568 Resistance of *Campylobacter* spp. Causing Human Infection in Australia: An International
569 Comparison. *Microb Drug Resist*. 2021;27(4):518-28. doi: 10.1089/mdr.2020.0082. PubMed
570 PMID: 32898460.
- 571 31. Zeng X, Brown S, Gillespie B, Lin J. A single nucleotide in the promoter region modulates the
572 expression of the β -lactamase OXA-61 in *Campylobacter jejuni*. *J Antimicrob Chemother*.
573 2014;69(5):1215-23. Epub 2014/01/11. doi: 10.1093/jac/dkt515. PubMed PMID: 24408987.
- 574 32. Ladely SR, Meinersmann RJ, Englen MD, Fedorka-Cray PJ, Harrison MA. 23S rRNA gene
575 mutations contributing to macrolide resistance in *Campylobacter jejuni* and *Campylobacter*
576 *coli*. *Foodborne Pathog Dis*. 2009;6(1):91-8. Epub 2008/11/19. doi: 10.1089/fpd.2008.0098.
577 PubMed PMID: 19014274.
- 578 33. Hakanen A, Jalava J, Kotilainen P, Jousimies-Somer H, Siitonen A, Huovinen P. *gyrA*
579 polymorphism in *Campylobacter jejuni*: detection of *gyrA* mutations in 162 *C. jejuni* isolates
580 by single-strand conformation polymorphism and DNA sequencing. *Antimicrob Agents*
581 *Chemother*. 2002;46(8):2644-7. Epub 2002/07/18. doi: 10.1128/aac.46.8.2644-2647.2002.
582 PubMed PMID: 12121947; PubMed Central PMCID: PMC127378.
- 583 34. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat*.
584 2010;13(6):151-71. Epub 2010/09/14. doi: 10.1016/j.drug.2010.08.003. PubMed PMID:
585 20833577; PubMed Central PMCID: PMC2992599.
- 586 35. Whitehouse CA, Young S, Li C, Hsu CH, Martin G, Zhao S. Use of whole-genome sequencing
587 for *Campylobacter* surveillance from NARMS retail poultry in the United States in 2015. *Food*
588 *Microbiol*. 2018;73:122-8. Epub 2018/03/13. doi: 10.1016/j.fm.2018.01.018. PubMed PMID:
589 29526197.
- 590 36. Qin S, Wang Y, Zhang Q, Zhang M, Deng F, Shen Z, et al. Report of ribosomal RNA methylase
591 gene *erm(B)* in multidrug-resistant *Campylobacter coli*. *J Antimicrob Chemother*.
592 2014;69(4):964-8. Epub 2013/12/18. doi: 10.1093/jac/dkt492. PubMed PMID: 24335515.
- 593 37. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-
594 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert
595 proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and*
596 *Infection*. 2012;18(3):268-81. doi: <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
- 597 38. Wiczorek K, Wołkowicz T, Osek J. Antimicrobial Resistance and Virulence-Associated Traits
598 of *Campylobacter jejuni* Isolated From Poultry Food Chain and Humans With Diarrhea.
599 *Frontiers in Microbiology*. 2018;9. doi: 10.3389/fmicb.2018.01508.
- 600 39. Quino W, Caro-Castro J, Hurtado V, Flores-León D, Gonzalez-Escalona N, Gavilan RG.
601 Genomic Analysis and Antimicrobial Resistance of *Campylobacter jejuni* and *Campylobacter*
602 *coli* in Peru. *Frontiers in Microbiology*. 2022;12. doi: 10.3389/fmicb.2021.802404.
- 603 40. Bravo V, Katz A, Porte L, Weitzel T, Varela C, Gonzalez-Escalona N, et al. Genomic analysis of
604 the diversity, antimicrobial resistance and virulence potential of clinical *Campylobacter jejuni*
605 and *Campylobacter coli* strains from Chile. *PLoS Negl Trop Dis*. 2021;15(2):e0009207. Epub
606 2021/02/20. doi: 10.1371/journal.pntd.0009207. PubMed PMID: 33606689; PubMed Central
607 PMCID: PMC7928456.
- 608 41. Breinman L, Cutler A, Liaw A, Wiener M. randomForest: Breiman and Cutler's Random
609 Forests for Classification and Regression 2022. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/randomForest/index.html)
610 [project.org/web/packages/randomForest/index.html](https://cran.r-project.org/web/packages/randomForest/index.html).
- 611 42. Kuhn M, Wing J, Weston S, Williams A, Keefer C, Engelhardt A, et al. caret: Classification and
612 Regression Training 2023. Available from: <https://cran.r-project.org/web/packages/caret/>.
- 613 43. Kooperberg C, Ruczinski I. LogicReg: Logic Regression. 2022.
- 614 44. Gibb S, Strimmer K. binda: Multi-Class Discriminant Analysis using Binary Predictors 2021.
615 Available from: <https://cran.r-project.org/web/packages/binda/index.html>.
- 616 45. R Core Team. R: A language and environment for statistical computing. R Foundation for
617 Statistical Computing. Vienna, Austria Available from: <https://www.R-project.org/>.

- 618 46. Wood S. mgcv: Mixed GAM Computation Vehicle with Automatic Smoothness Estimation
619 2023. Available from: <https://cran.r-project.org/web/packages/mgcv/index.html>.
- 620 47. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree
621 display and annotation. *Nucleic Acids Research*. 2021;49(W1):W293-W6. doi:
622 10.1093/nar/gkab301.
- 623 48. Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, et al. ggplot2: Create
624 Elegant Data Visualisations Using the Grammar of Graphics 2023. Available from:
625 <https://cran.r-project.org/web/packages/ggplot2/index.html>.
- 626 49. Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton
627 pump inhibitors alter the composition of the gut microbiota. *Gut*. 2016;65(5):749-56. Epub
628 2015/12/30. doi: 10.1136/gutjnl-2015-310861. PubMed PMID: 26719299.
- 629 50. Chen Y, Liu B, Glass K, Du W, Banks E, Kirk M. Use of Proton Pump Inhibitors and the Risk of
630 Hospitalization for Infectious Gastroenteritis. *PloS one*. 2016;11(12):e0168618-e. doi:
631 10.1371/journal.pone.0168618. PubMed PMID: 27997598.
- 632 51. González-Hein G, Huaracán B, García P, Figueroa G. Prevalence of virulence genes in strains
633 of *Campylobacter jejuni* isolated from human, bovine and broiler. *Braz J Microbiol*.
634 2013;44(4):1223-9. Epub 2014/04/02. doi: 10.1590/s1517-83822013000400028. PubMed
635 PMID: 24688515; PubMed Central PMCID: PMC3958191.
- 636 52. Biswas D, Hannon SJ, Townsend HG, Potter A, Allan BJ. Genes coding for virulence
637 determinants of *Campylobacter jejuni* in human clinical and cattle isolates from Alberta,
638 Canada, and their potential role in colonization of poultry. *Int Microbiol*. 2011;14(1):25-32.
639 Epub 2011/10/22. doi: 10.2436/20.1501.01.132. PubMed PMID: 22015699.
- 640 53. Lluque A, Riveros M, Prada A, Ochoa TJ, Ruiz J. Virulence and Antimicrobial Resistance in
641 *Campylobacter* spp. from a Peruvian Pediatric Cohort. *Scientifica (Cairo)*.
642 2017;2017:7848926. Epub 2017/11/14. doi: 10.1155/2017/7848926. PubMed PMID:
643 29130018; PubMed Central PMCID: PMC5654289.
- 644 54. Casabonne C, Gonzalez A, Aquili V, Subils T, Balague C. Prevalence of Seven Virulence Genes
645 of *Campylobacter jejuni* Isolated from Patients with Diarrhea in Rosario, Argentina.
646 2016;3(4):e37727. Epub 2016-08-01. doi: 10.17795/iji-37727.
- 647 55. Kim JS, Lee MY, Kim SJ, Jeon S-E, Cha I, Hong S, et al. High-Level Ciprofloxacin-Resistant
648 *Campylobacter jejuni* Isolates Circulating in Humans and Animals in Incheon, Republic of
649 Korea. *Zoonoses and Public Health*. 2016;63(7):545-54. doi:
650 <https://doi.org/10.1111/zph.12262>.
- 651 56. Marsden GL, Li J, Everest PH, Lawson AJ, Ketley JM. Creation of a Large Deletion Mutant of
652 *Campylobacter jejuni* Reveals that the Lipooligosaccharide Gene Cluster Is Not
653 Required for Viability. *Journal of Bacteriology*. 2009;191(7):2392-9. doi:
654 doi:10.1128/jb.01397-08.
- 655 57. Moffatt CRM, Kennedy KJ, Selvey L, Kirk MD. *Campylobacter*-associated hospitalisations in
656 an Australian provincial setting. *BMC Infectious Diseases*. 2021;21(1):10. doi:
657 10.1186/s12879-020-05694-0.
- 658 58. White AE, Ciampa N, Chen Y, Kirk M, Nesbitt A, Bruce BB, et al. Characteristics of
659 *Campylobacter* and *Salmonella* Infections and Acute Gastroenteritis in Older Adults in
660 Australia, Canada, and the United States. *Clin Infect Dis*. 2019;69(9):1545-52. Epub
661 2019/01/03. doi: 10.1093/cid/ciy1142. PubMed PMID: 30602004; PubMed Central PMCID:
662 PMC6606397.
- 663 59. Quetz JdS, Lima IFN, Havt A, Prata MMG, Cavalcante PA, Medeiros PHQS, et al.
664 *Campylobacter jejuni* infection and virulence-associated genes in children with moderate to
665 severe diarrhoea admitted to emergency rooms in northeastern Brazil. *Journal of Medical
666 Microbiology*. 2012;61(4):507-13. doi: <https://doi.org/10.1099/jmm.0.040600-0>.
- 667 60. Kamal N, Dorrell N, Jagannathan A, Turner SM, Constantinidou C, Studholme DJ, et al.
668 Deletion of a previously uncharacterized flagellar-hook-length control gene *fliK* modulates

- 669 the σ^{54} -dependent regulon in *Campylobacter jejuni*. *Microbiology*. 2007;153(9):3099-111.
670 doi: <https://doi.org/10.1099/mic.0.2007/007401-0>.
- 671 61. Javed MA, Cawthraw SA, Baig A, Li J, McNally A, Oldfield NJ, et al. Cj1136 is required for
672 lipooligosaccharide biosynthesis, hyperinvasion, and chick colonization by *Campylobacter*
673 *jejuni*. *Infect Immun*. 2012;80(7):2361-70. Epub 20120416. doi: 10.1128/iai.00151-12.
674 PubMed PMID: 22508861; PubMed Central PMCID: PMC3416457.
- 675 62. Rukambile E, Sintchenko V, Muscatello G, Kock R, Alders R. Infection, colonization and
676 shedding of *Campylobacter* and *Salmonella* in animals and their contribution to human
677 disease: A review. *Zoonoses and public health*. 2019;66(6):562-78.
- 678 63. Lopes GV, Ramires T, Kleinubing NR, Scheik LK, Fiorentini ÂM, Padilha da Silva W. Virulence
679 factors of foodborne pathogen *Campylobacter jejuni*. *Microbial Pathogenesis*.
680 2021;161:105265. doi: <https://doi.org/10.1016/j.micpath.2021.105265>.
- 681 64. Bacon DJ, Szymanski CM, Burr DH, Silver RP, Alm RA, Guerry P. A phase-variable capsule is
682 involved in virulence of *Campylobacter jejuni* 81-176. *Molecular Microbiology*.
683 2001;40(3):769-77. doi: <https://doi.org/10.1046/j.1365-2958.2001.02431.x>.
- 684 65. Konkel ME, Monteville MR, Rivera-Amill V, Joens LA. The pathogenesis of *Campylobacter*
685 *jejuni*-mediated enteritis. *Current issues in intestinal microbiology*. 2001;2(2):55-71.
- 686 66. Ghunaim H, Behnke JM, Aigha I, Sharma A, Doiphode SH, Deshmukh A, et al. Analysis of
687 Resistance to Antimicrobials and Presence of Virulence/Stress Response Genes in
688 *Campylobacter* Isolates from Patients with Severe Diarrhoea. *PLOS ONE*.
689 2015;10(3):e0119268. doi: 10.1371/journal.pone.0119268.
- 690 67. Kreling V, Falcone FH, Kehrenberg C, Hensel A. *Campylobacter* sp.: Pathogenicity factors and
691 prevention methods—new molecular targets for innovative antivirulence drugs? *Applied*
692 *Microbiology and Biotechnology*. 2020;104(24):10409-36. doi: 10.1007/s00253-020-10974-
693 5.
- 694 68. Whitehouse CA, Balbo PB, Pesci EC, Cottle DL, Mirabito PM, Pickett CL. *Campylobacter jejuni*
695 cytolethal distending toxin causes a G2-phase cell cycle block. *Infect Immun*.
696 1998;66(5):1934-40. Epub 1998/05/09. doi: 10.1128/iai.66.5.1934-1940.1998. PubMed
697 PMID: 9573072; PubMed Central PMCID: PMC108146.
- 698 69. Hickey TE, McVeigh AL, Scott DA, Michielutti RE, Bixby A, Carroll SA, et al. *Campylobacter*
699 *jejuni* cytolethal distending toxin mediates release of interleukin-8 from intestinal epithelial
700 cells. *Infect Immun*. 2000;68(12):6535-41. Epub 2000/11/18. doi: 10.1128/iai.68.12.6535-
701 6541.2000. PubMed PMID: 11083762; PubMed Central PMCID: PMC97747.
- 702 70. Asakura M, Samosornsuk W, Hinenoya A, Misawa N, Nishimura K, Matsuhisa A, et al.
703 Development of a cytolethal distending toxin (cdt) gene-based species-specific multiplex PCR
704 assay for the detection and identification of *Campylobacter jejuni*, *Campylobacter coli* and
705 *Campylobacter fetus*. *FEMS Immunol Med Microbiol*. 2008;52(2):260-6. Epub 2008/02/06.
706 doi: 10.1111/j.1574-695X.2007.00369.x. PubMed PMID: 18248435.
- 707 71. Park SF. The physiology of *Campylobacter* species and its relevance to their role as
708 foodborne pathogens. *International Journal of Food Microbiology*. 2002;74(3):177-88. doi:
709 [https://doi.org/10.1016/S0168-1605\(01\)00678-X](https://doi.org/10.1016/S0168-1605(01)00678-X).
- 710 72. Lapierre L, Gatica MA, Riquelme V, Vergara C, Yañez JM, San Martin B, et al. Characterization
711 of antimicrobial susceptibility and its association with virulence genes related to adherence,
712 invasion, and cytotoxicity in *Campylobacter jejuni* and *Campylobacter coli* isolates from
713 animals, meat, and humans. *Microbial Drug Resistance*. 2016;22(5):432-44.
- 714 73. Hansson I, Sandberg M, Habib I, Lowman R, Engvall EO. Knowledge gaps in control of
715 *Campylobacter* for prevention of campylobacteriosis. *Transboundary and Emerging Diseases*.
716 2018;65(S1):30-48. doi: <https://doi.org/10.1111/tbed.12870>.
- 717 74. Godschalk PCR, Kuijf ML, Li J, Michael FS, Ang CW, Jacobs BC, et al. Structural
718 Characterization of *Campylobacter jejuni* Lipooligosaccharide Outer Cores Associated with

- 719 Guillain-Barré and Miller Fisher Syndromes. *Infection and Immunity*. 2007;75(3):1245-54.
720 doi: doi:10.1128/IAI.00872-06.
- 721 75. Therapeutic Guidelines Limited. Acute infectious diarrhoea 2022 [cited 2023 26 June].
722 Available from:
723 [https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=ac](https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=acute-gastroenteritis&guidelinename=Antibiotic§ionId=toc_d1e521#toc_d1e521)
724 [ute-gastroenteritis&guidelinename=Antibiotic§ionId=toc_d1e521#toc_d1e521](https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=acute-gastroenteritis&guidelinename=Antibiotic§ionId=toc_d1e521#toc_d1e521).
- 725 76. Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone
726 resistance through successful regulation, Australia. *Emerg Infect Dis*. 2012;18(9):1453-60.
727 doi: 10.3201/eid1809.111515. PubMed PMID: 22932272; PubMed Central PMCID:
728 PMC3437704.
- 729 77. Andrzejewska M, Grudlewska-Buda K, Śpica D, Skowron K, Ćwiklińska-Jurkowska M, Szady-
730 Grad M, et al. Genetic relatedness, virulence, and drug susceptibility of *Campylobacter*
731 isolated from water and wild birds. *Frontiers in Cellular and Infection Microbiology*. 2022;12.
732 doi: 10.3389/fcimb.2022.1005085.
- 733 78. Wysok B, Wojtacka J, Kivistö R. Pathogenicity of *Campylobacter* strains of poultry and human
734 origin from Poland. *International Journal of Food Microbiology*. 2020;334:108830. doi:
735 <https://doi.org/10.1016/j.ijfoodmicro.2020.108830>.
- 736
737

738 Figure captions

739 **Fig 1. (a) Symptom profiles of Australian campylobacteriosis cases (muscle and body aches,**
740 **nausea, and stomach cramps), 2018–2019. (b) Symptom profiles of Australian campylobacteriosis**
741 **cases (blood in stool, fever, headache, and vomiting), 2018–2019. (c) Course of disease**
742 **characteristics of Australian campylobacteriosis cases (hospitalisation, hospitalisation ≥ 3 days,**
743 **length of illness ≥ 7 days), 2018–2019. The solid lines indicate estimated prevalence from a**
744 **univariable generalised additive model with a logit link. Shading around each line represents the 95%**
745 **confidence interval for the prevalence estimate.**

746 **Fig 2. Distribution of modified Vesikari Scoring System scores for 571 campylobacteriosis cases in**
747 **Australia, 2018–2019. Bars represent the percentage of cases reporting the corresponding Vesikari**
748 **Score. Error bars are calculated from binomial confidence intervals using the Pearson-Klopper exact**
749 **method. Counts are provided above the bar for each Vesikari Score.**

750 **Fig 3. Distribution of modified Vesikari Scoring System scores by age for 571 campylobacteriosis**
751 **cases in Australia, 2018–2019. The solid line indicates the estimated score from a generalised**
752 **additive model with a logit link. Shading around the line represents the 95% confidence interval for**
753 **the score estimate.**

754 **Fig 4. Genotypic antimicrobial resistance profiles of 506 *Campylobacter* isolates for ampicillin**
755 **(AMP), ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), and tetracycline (TET). Isolates**
756 **were classified as susceptible if they did not possess a known resistance gene or mutation ($n = 403$).**
757 **The number of isolates possessing each resistance profile is noted above the respective bar. Error bars**
758 **are calculated from binomial confidence intervals using the Pearson-Klopper exact method.**

759 Supporting Information

760 **S1 Table: Antimicrobial resistance genes and mutations used to infer phenotypic resistance in**
761 ***Campylobacter* isolates.**

762 **S2 Table. Summary of *Campylobacter* isolates ($n = 1122$) included in this study.**

763 **S3 Table. Univariable results for hospitalisation, adjusted for age group, sex, and location, and**
764 **final multivariable model. OR: odds ratio, aOR: adjusted odds ratio, CI: confidence interval, ref:**
765 **reference category, Inf: no limit on confidence interval.**

766 **S4 Table. Univariable results for prescription of antibiotics following illness, adjusted for age**
767 **group, sex, and location, and final multivariable model. OR: odds ratio, aOR: adjusted odds ratio, CI:**
768 **confidence interval, ref: reference category, Inf: no limit on confidence interval.**

769 **S5 Table. Univariable results for length of diarrhoeal illness, adjusted for age group, sex, and**
770 **location, and final multivariable model. OR: odds ratio, aOR: adjusted odds ratio, CI: confidence**
771 **interval, ref: reference category, Inf: no limit on confidence interval.**

772 **S6 Table: Summary of multi-locus sequence type (MLST) and virulence gene prevalence in**
773 ***Campylobacter jejuni* and *C. coli* human isolates.**

774 **S7 Table. Comparison of isolate virulence gene prevalence between human and retail meat**
775 **isolates, Australia, 2018–2019. N/A: no gene present, or no analysis possible due to zero levels. ***
776 **indicates significant result ($p < 0.05$).**

777 **S1 Fig. Prevalence of virulence genes and gene clustering by multi-locus sequence type (MLST) for**
778 ***C. jejuni* human isolates. The colour scale represents the proportion of isolates within each MLST**
779 **expressing each virulence gene.**

780 **S2 Fig. Prevalence of virulence genes and gene clustering by multi-locus sequence type (MLST) for**
781 ***C. coli* human isolates.** The colour scale represents the proportion of isolates within each MLST
782 expressing each virulence gene.

783 **S3 Fig. Maximum likelihood phylogenetic tree showing the core genome relationship between *C.***
784 ***jejuni* isolates ($n = 422$) from humans in the Australian Capital Territory (ACT), New South Wales**
785 **(NSW), and Queensland (Qld).** The circle lanes from inner to outer indicate jurisdiction, multilocus
786 sequence type (MLST), the number of class of antimicrobial genotype detected, and the number and
787 trait class of virulence genotype detected.

788 **S4 Fig. Maximum likelihood phylogenetic tree showing the core genome relationship between *C.***
789 ***coli* isolates ($n = 84$) from humans in the Australian Capital Territory (ACT), New South Wales**
790 **(NSW), and Queensland (QLD).** The circle lanes from inner to outer indicate jurisdiction, multilocus
791 sequence type (MLST), the number and class of antimicrobial genotype detected, and the number
792 and trait class of virulence genotype detected.

793 **S5 Fig. Relative importance by Gini* coefficient of *Campylobacter jejuni* virulence genes for**
794 **predicting case isolates^ compared with meat isolates in Australia, 2018–2019.** * Mean decrease in
795 Gini coefficient measures how much of each variable contributes to the homogeneity of the nodes
796 and leaves in the random forest. The higher the value of mean decrease Gini score, the higher the
797 importance of the variable. Values should be considered relative to those of other variables rather
798 than absolute values. ^Genes more common in case isolates include *fliK*, *Cj1136*, *Cj1138*, *Cj1135*, *maf4*,
799 *neuC*, *rfaC*, *wlaN*, *cysC*, *Cj1422c*, *Cj1421c*, *gmhA2*, *kpsC*, *waaV*, *fcl*, *Cj1420c*, *ciaB*, and *Cj1419c* although
800 not all differences in gene prevalence are significant ($p < 0.05$).

801 **S1 File. Random Forest model outputs for *Campylobacter jejuni* and *C. coli* determining virulence**
802 **genes that predict hospitalisation or length of diarrhoeal illness in Australia, 2018–2019.**

803 **S2 File. Random Forest model outputs determining virulence genes that predict a human case**
804 **compared with retail meat and offal isolates in Australia, 2018–2019.**

805